SONN Pemfailan SEC - Sonnet BioTherapeutics Holdings, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

LEI	5493002WX622LZQC4F93
CIK	1106838

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sonnet BioTherapeutics Holdings, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

August 26, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
August 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35570 SONNET BIO
August 1, 2025	EX-10.1	Employment Agreement by and between the Company and Raghu Rao, dated July 31, 2025. Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), dated as of July 31, 2025 is by and between RAGHU RAO. (the “Executive”) and SONNET BIOTHERAPEUTICS, INC., a New Jersey corporation (the “Company”). WHEREAS, on July 31, 2025, the Board of Directors of the Company approved the employment of the Executive as its Chief Executive Officer with certain co
August 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2025 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
July 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 23, 2025 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 23, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
July 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2025 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
July 14, 2025	EX-2.1	Business Combination Agreement. EXHIBIT 2.1 BUSINESS COMBINATION AGREEMENT by and among HYPERLIQUID STRATEGIES INC, RORSCHACH MERGER SUB LLC TBS MERGER SUB INC, RORSCHACH I LLC and SONNET BIOTHERAPEUTICS HOLDINGS, INC. Dated as of July 11, 2025 Table of Contents Page ARTICLE I. DEFINITIONS 3 Section 1.01 Certain Definitions 3 Section 1.02 Further Definitions 14 Section 1.03 Construction 17 ARTICLE II. AGREEMENT AND PLAN OF MERGE
July 14, 2025	EX-10.3	Form of PIPE Purchase Agreement. EXHIBIT 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 11, 2025, between Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation, and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions s
July 14, 2025	EX-3.1	Certificate of Designations. EXHIBIT 3.1 SONNET BIOTHERAPEUTICS HOLDINGS, Inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES 5 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Raghu Rao, does hereby certify that: 1. The undersigned is the Interim Chief Executive Officer of Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (th
July 14, 2025	EX-10.1	Form of Contribution Agreement. EXHIBIT 10.1 THE MEMBERSHIP INTERESTS DESCRIBED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER RESTRICTIONS ON THE TRANSFERABILITY OF THE MEMBERSHIP INTERESTS DESCRIBED HEREIN. THE PURCHASE OF THE MEMBERSHIP INTERESTS INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEA
July 14, 2025	EX-3.1	Certificate of Designations. EXHIBIT 3.1 SONNET BIOTHERAPEUTICS HOLDINGS, Inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES 5 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Raghu Rao, does hereby certify that: 1. The undersigned is the Interim Chief Executive Officer of Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (th
July 14, 2025	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2025 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
July 14, 2025	EX-10.2	Form of Subscription Agreement. EXHIBIT 10.2 THE SECURITIES DESCRIBED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER RESTRICTIONS ON THE TRANSFERABILITY OF THE SECURITIES DESCRIBED HEREIN. THE PURCHASE OF THE SECURITIES INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEAR THE RISK OF THE LOSS OF THEI
July 14, 2025	EX-10.1	Form of Contribution Agreement. EXHIBIT 10.1 THE MEMBERSHIP INTERESTS DESCRIBED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER RESTRICTIONS ON THE TRANSFERABILITY OF THE MEMBERSHIP INTERESTS DESCRIBED HEREIN. THE PURCHASE OF THE MEMBERSHIP INTERESTS INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEA
July 14, 2025	EX-4.1	Form of PIPE Warrant. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 14, 2025	EX-99.1	Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury Exhibit 99.1 Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury PRINCETON, NJ, July 14, 2025 — Sonnet BioTherapeutics, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has entered into a d
July 14, 2025	EX-2.1	Business Combination Agreement. EXHIBIT 2.1 BUSINESS COMBINATION AGREEMENT by and among HYPERLIQUID STRATEGIES INC, RORSCHACH MERGER SUB LLC TBS MERGER SUB INC, RORSCHACH I LLC and SONNET BIOTHERAPEUTICS HOLDINGS, INC. Dated as of July 11, 2025 Table of Contents Page ARTICLE I. DEFINITIONS 3 Section 1.01 Certain Definitions 3 Section 1.02 Further Definitions 14 Section 1.03 Construction 17 ARTICLE II. AGREEMENT AND PLAN OF MERGE
July 14, 2025	EX-10.2	Form of Subscription Agreement. EXHIBIT 10.2 THE SECURITIES DESCRIBED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER RESTRICTIONS ON THE TRANSFERABILITY OF THE SECURITIES DESCRIBED HEREIN. THE PURCHASE OF THE SECURITIES INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEAR THE RISK OF THE LOSS OF THEI
July 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2025 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
July 14, 2025	EX-10.3	Form of PIPE Purchase Agreement. EXHIBIT 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 11, 2025, between Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation, and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions s
July 14, 2025	EX-99.1	Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury Exhibit 99.1 Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury PRINCETON, NJ, July 14, 2025 — Sonnet BioTherapeutics, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has entered into a d
July 14, 2025	EX-4.1	Form of PIPE Warrant. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 2, 2025	EX-4.2	Form of Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 2, 2025	EX-4.1	Form of Convertible Note Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR AN OPINION OF COUNSEL IN FORM, SUBSTANCE AND SCOPE CUSTOMARY FOR OPINIONS OF COUNSEL IN COMPARABLE TRANSACTION
July 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2025 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
June 2, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35570 SONNET BI
April 4, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
April 1, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation
March 26, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2025 SONNET BIOTHERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation
March 19, 2025	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation
March 19, 2025	EX-99.1	Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18Binding Protein Resistant Variant Protein Sonnet’s variant human IL-18BPR is a key cytokine which comp Exhibit 99.1 Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18Binding Protein Resistant Variant Protein Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with un
February 26, 2025	EX-99.1	Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors Poster presented at the 2025 AACR:IO Conference Company’s novel platform tha Exhibit 99.1 Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors Poster presented at the 2025 AACR:IO Conference Company’s novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (FHAB®) provides enhanced t
February 26, 2025	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporat
February 19, 2025	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 19, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporat
February 19, 2025	EX-99.1	Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates Building on proven targeting of the FHAB domain, Exhibit 99.1 Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates Building on proven targeting of the FHAB domain, Sonnet’s ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2
February 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35570 SONNET
February 13, 2025	EX-10.6	Employment Agreement by and between the Company and Stephen McAndrew, Ph.D., dated February 12, 2025. Exhibit 10.6 EXECUTIVE EMPLOYMENT AGREEMENT THE EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), dated as of February 12, 2025 and effective as of the Effective Date (as defined below) is by and between STEPHEN MCANDREW (the “Executive”) and SONNET BIOTHERAPEUTICS, INC., a New Jersey corporation (the “Company”). WHEREAS, the Executive has been employed as the Company’s SVP of Business Development
February 13, 2025	EX-99.1	Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update Exhibit 99.1 Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial. Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR) Continued progress with clin
February 13, 2025	8-K	Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporat
January 31, 2025	424B3	127,500 Shares of Common Stock 545,500 Shares of Common Stock issuable upon exercise of 545,500 Outstanding Pre-Funded Warrants 1,758,325 Shares of Common Stock issuable upon exercise of 1,758,325 Outstanding Common Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-284409 PROSPECTUS 127,500 Shares of Common Stock 545,500 Shares of Common Stock issuable upon exercise of 545,500 Outstanding Pre-Funded Warrants 1,758,325 Shares of Common Stock issuable upon exercise of 1,758,325 Outstanding Common Warrants This prospectus relates to the resale from time to time, by the selling stockholders identified in this
January 31, 2025	424B3	Up to 2,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-284409 PROSPECTUS Up to 2,000,000 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by Chardan Capital Markets LLC (“Chardan” or the “Selling Securityholder”) of up to 2,000,000 shares of our common stock, $0.0001 par value per share (“Common Stock”), that have been or may be issued by us to Charda
January 30, 2025	S-1/A	As filed with the Securities and Exchange Commission on January 30, 2025 As filed with the Securities and Exchange Commission on January 30, 2025 Registration No.
January 30, 2025	S-1/A	As filed with the Securities and Exchange Commission on January 30, 2025 As filed with the Securities and Exchange Commission on January 30, 2025 Registration No.
January 28, 2025	CORRESP	January 28, 2025 January 28, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
January 28, 2025	CORRESP	January 28, 2025 January 28, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
January 28, 2025	EX-99.1	Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding ( Exhibit 99.1 Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) domain fusion proteins In addition to the U.S. and EU, Sonnet’s global IP coverage now extends to China, Japan, Russia and New Zea
January 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 SONNET BIOTHERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporati
January 22, 2025	S-1	As filed with the Securities and Exchange Commission on January 22, 2025 As filed with the Securities and Exchange Commission on January 22, 2025 Registration No.
January 22, 2025	S-1	As filed with the Securities and Exchange Commission on January 22, 2025 As filed with the Securities and Exchange Commission on January 22, 2025 Registration No.
January 22, 2025	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
January 22, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
January 21, 2025	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporati
January 21, 2025	EX-99.1	Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid Exhibit 99.1 Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with the potential to improve trabectedin’s therapeutic window in sof
January 21, 2025	424B3	Up to 625,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-280705 PROSPECTUS Up to 625,000 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by Chardan Capital Markets LLC (“Chardan” or the “Selling Securityholder”) of up to 625,000 shares of our common stock, $0.0001 par value per share (“Common Stock”), that have been or may be issued by us to Chardan pu
January 13, 2025	POS AM	As filed with the Securities and Exchange Commission on January 13, 2025 As filed with the Securities and Exchange Commission on January 13, 2025 Registration No.
December 17, 2024	8-K	Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporat
December 17, 2024	EX-4.8	Exhibit 4.8 Exhibit 4.8 DESCRIPTION OF SONNET BIOTHERAPEUTICS HOLDINGS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Sonnet BioTherapeutics Holdings, Inc. (“us,” “our,” “we” or the “Company”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our voting common stock, $0.0001 par value per share and preferr
December 17, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35570 SONNET BIOTHE
December 17, 2024	EX-19.1	Insider Trading Policy.* Exhibit 19.1 SONNET BIOTHERAPEUTICS HOLDINGS, INC. INSIDER TRADING POLICY As Amended and Restated by the Board on December 16, 2024 The following Insider Trading Policy (“Policy”) has been approved by the Board of Directors (the “Board”) of Sonnet BioTherapeutics Holdings, Inc. (together with its subsidiaries, the “Company”). Two copies of this Policy are being provided to you. You must read, sign
December 17, 2024	EX-99.1	Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing a Exhibit 99.1 Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN) Multiple value-driving mile
December 10, 2024	EX-4.2	Form of Private Placement Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on December 10, 2024). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
December 10, 2024	EX-4.3	Form of Common Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on December 10, 2024). Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
December 10, 2024	EX-4.1	Form of Registered Direct Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 10, 2024). Exhibit 4.1 FORM OF PRE-FUNDED WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: [ ] (“Issuance Date”) Sonnet BioTherapeutics Holdings, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and suffi
December 10, 2024	424B5	768,000 Shares of Common Stock 317,325 Pre-Funded Warrants to Purchase up to 317,325 Shares of Common Stock 317,325 Shares of Common Stock Underlying the 317,325 Pre-Funded Warrants PROSPECTUS SUPPLEMENT (To Prospectus dated January 4, 2024) Filed Pursuant to Rule 424(b)(5) Registration No.
December 10, 2024	EX-10.1	Form of Registered Direct Securities Purchase Agreement, dated December 9, 2024, by and between the Company and the Purchasers (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on December 10, 2024). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 9, 2024, between Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the term
December 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 9, 2024 SONNET BIOTHERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 9, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction of Incorporation)
December 10, 2024	EX-10.2	Form of Private Placement Securities Purchase Agreement, dated December 9, 2024, by and between the Company and the Purchasers (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on December 10, 2024). Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 9, 2024, between Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the term
December 10, 2024	EX-99.1	Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At- The-Market Under Nasdaq Rules Exhibit 99.1 December 9, 2024 Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At- The-Market Under Nasdaq Rules PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it
December 9, 2024	EX-99.1	Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or Exhibit 99.1 Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months post-initiation of dosing was seen in 10 of 21
December 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 SONNET BIOTHERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporati
December 4, 2024	EX-99.1	Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action Pankaj Mohan, CEO of Sonnet discusses what this publication means in a Vi Exhibit 99.1 Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action Pankaj Mohan, CEO of Sonnet discusses what this publication means in a Virtual Investor “What This Means” segment; access here PRINCETON, NJ, December 4, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings,
December 4, 2024	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporati
November 26, 2024	EX-FILING FEES	Filing Fee Table* Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
November 26, 2024	S-8	As filed with the Securities and Exchange Commission on November 26, 2024 As filed with the Securities and Exchange Commission on November 26, 2024 Registration No.
November 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2024 SONNET BIOTHERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction (Commission (IRS E
November 8, 2024	EX-99.1	Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 November 6, 2024 Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) - Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced the pricing of an
November 8, 2024	EX-1.1	Underwriting Agreement, dated November 6, 2024, between the Company and Chardan Capital Markets, LLC (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 8, 2024). Exhibit 1.1 EXECUTION VERSION SONNET BIOTHERAPEUTICS HOLDINGS, INC. UNDERWRITING AGREEMENT November 6, 2024 CHARDAN CAPITAL MARKETS, LLC 17 State Street, Suite 2100 New York, NY 10004 As Representative of the several Underwriters (as defined herein) Ladies and Gentlemen: Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions sta
November 7, 2024	424B4	155,000 Shares of Common Stock 956,111 Pre-Funded Warrants to Purchase up to 956,111 Shares of Common Stock 1,111,111 Common Warrants to Purchase up to 2,222,222 Shares of Common Stock 956,111 Shares of Common Stock issuable upon exercise of the Pre- Filed Pursuant to Rule 424(b)(4) Registration No. 333-282850 PROSPECTUS 155,000 Shares of Common Stock 956,111 Pre-Funded Warrants to Purchase up to 956,111 Shares of Common Stock 1,111,111 Common Warrants to Purchase up to 2,222,222 Shares of Common Stock 956,111 Shares of Common Stock issuable upon exercise of the Pre-Funded Warrants 2,222,222 Shares of Common Stock issuable upon exercise of the
November 6, 2024	CORRESP	[Signature Page to Follow] November 6, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Sonnet BioTherapeutics Holdings, Inc. Registration Statement on Form S-1, as amended File No. 333-282850 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of
November 6, 2024	EX-4.22	Form of Common Warrant (incorporated by reference to Exhibit 4.22 of the Company’s Registration Statement on Form S-1/A filed with the SEC on November 6, 2024). Exhibit 4.22 FORM OF COMMON WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: [ ], 2024 (“Issuance Date”) Sonnet BioTherapeutics Holdings, Inc., a company organized under the law of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of
November 6, 2024	CORRESP	November 6, 2024 November 6, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 6, 2024	EX-99.1	Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet’s FHAB pl Exhibit 99.1 Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP) IL-18 has significa
November 6, 2024	CORRESP	November 6, 2024 November 6, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 6, 2024	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 SONNET BIOTHERAPEUTICS HOLDINGS, INC. UNDERWRITING AGREEMENT November [ ● ], 2024 CHARDAN CAPITAL MARKETS, LLC 17 State Street, Suite 2100 New York, NY 10004 As Representative of the several Underwriters (as defined herein) Ladies and Gentlemen: Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to
November 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 SONNET BIOTHERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporati
November 6, 2024	CORRESP	November 6, 2024 November 6, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 6, 2024	CORRESP	November 6, 2024 November 6, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 6, 2024	EX-4.23	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.23 to the Company’s Registration Statement on Form S-1/A filed with the SEC on November 6, 2024). Exhibit 4.23 FORM OF PRE-FUNDED WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: [ ] (“Issuance Date”) Sonnet BioTherapeutics Holdings, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and suff
November 6, 2024	S-1/A	As filed with the Securities and Exchange Commission on November 6, 2024 As filed with the Securities and Exchange Commission on November 6, 2024 Registration No.
November 6, 2024	CORRESP	[Signature Page to Follow] November 6, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Sonnet BioTherapeutics Holdings, Inc. Registration Statement on Form S-1, as amended File No. 333-282850 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of
November 4, 2024	S-1/A	As filed with the Securities and Exchange Commission on November 4, 2024 As filed with the Securities and Exchange Commission on November 4, 2024 Registration No.
October 28, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
October 28, 2024	S-1	As filed with the Securities and Exchange Commission on October 28, 2024 As filed with the Securities and Exchange Commission on October 28, 2024 Registration No.
October 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 SONNET BIOTHERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporati
October 17, 2024	EX-99.1	Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq Exhibit 99.1 Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq PRINCETON, NJ / Globe Newswire / October 17, 2024 / Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it received notice on October 16, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company reg
October 9, 2024	EX-10.1	License Agreement, dated October 8, 2024, between Sonnet BioTherapeutics, Inc., Sonnet BioTherapeutics CH SA and Alkem Laboratories Limited (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 9, 2024). Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]” LICENSE AGREEMENT between SONNET BIOTHERAPEUTICS, INC and ALKEM LABORATORIES LIMITED Dated as of October 8
October 9, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporatio
October 9, 2024	EX-99.1	Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India Sonnet to receive $1.0 million in upfront payment and up to an addition Exhibit 99.1 Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India Sonnet to receive $1.0 million in upfront payment and up to an additional $1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India market Al
September 30, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 Sonnet BioTherapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorpora
September 30, 2024	EX-3.1	Certificate of Amendment of Certificate of Incorporation, as amended, of Sonnet BioTherapeutics Holdings, Inc., dated September 25, 2024 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on September 30, 2024). Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF SONNET BIOTHERAPEUTICS HOLDINGS, INC. Sonnet BioTherapeutics Holdings, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: FIRST: That a resolution was duly adopted on August 7, 2024, by the Board of Dire
September 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 SONNET BIOTHER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorpora
September 18, 2024	EX-99.1	Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safet Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ / GlobeNewswire / September
September 12, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 Sonnet BioTherapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorpora
September 9, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction (Commission (IRS
September 9, 2024	EX-99.1	Corporate Presentation by Sonnet BioTherapeutics Holdings, Inc. Exhibit 99.1
August 30, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction (Commission (IR
August 19, 2024	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporatio
August 19, 2024	EX-99.1	Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer Preclinical data has demonstrated t Exhibit 99.1 Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy An Innovative
August 19, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35570 SONNET BIO
August 14, 2024	EX-99.1	Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Partners Exhibit 99.1 Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Partnership efforts to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN) underway Granted composi
August 14, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporatio
August 9, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction (Commission (IRS
August 9, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
July 24, 2024	EX-99.2	What this Means: Sonnet BioTherapeutics Data from SON-080 Phase 1b/2 Study in Chemotherapy Induced Peripheral Neuropathy (CIPN) Exhibit 99.2 What this Means: Sonnet BioTherapeutics Data from SON-080 Phase 1b/2 Study in Chemotherapy Induced Peripheral Neuropathy (CIPN) Participants: ● Pankaj Mohan, PhD – Founder and Chief Executive Officer ● Richard Kenney, M.D. – Chief Medical Officer ● Gael Hedou, PhD – Chief Operating Officer Sonnet BioTherapeutics (Nasdaq: SONN) Introduction: Jenene Thomas ● Welcome back for another Wha
July 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
July 24, 2024	EX-99.1	Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study Exhibit 99.1 Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study ● Data indicates that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine response ● Pain and quality of life survey results suggest the potential for rapid impr
July 15, 2024	424B3	5,770,140 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-280705 PROSPECTUS 5,770,140 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale of up to 5,770,140 shares of Sonnet BioTherapeutics Holdings, Inc. (the “Company,” “we,” “our” or “us”) common stock, $0.0001 par value per share (the “Common Stock”), by the Selling Stockholders listed in this
July 11, 2024	CORRESP	July 11, 2024 July 11, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
July 5, 2024	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
July 5, 2024	S-3	As filed with the Securities and Exchange Commission on July 5, 2024 As filed with the Securities and Exchange Commission on July 5, 2024 Registration No.
June 20, 2024	EX-10.1	Form of Inducement Letter (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 20, 2024). Exhibit 10.1 SONNET BIOTHERAEPEUTICS HOLDINGS, INC. June 19, 2024 Holder of Common Stock Purchase Warrants issued on October 27, 2023 Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Sonnet BioTherapeutics Holdings, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the Common Stock Purchase Warrants to purchase an aggregate of 2,828,500
June 20, 2024	EX-99.1	Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds Exhibit 99.1 Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) – Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the entry into a definitive agreement for the immediate exercise of certain outst
June 20, 2024	EX-4.1	Form of Common Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 20, 2024). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 20, 2024	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
June 20, 2024	EX-4.2	Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed with the SEC on June 20, 2024). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 14, 2024	EX-99.1	Presentation by Sonnet BioTherapeutics Holdings, Inc., dated June 13, 2024 Exhibit 99.1
June 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction (Commission (IRS Empl
June 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
June 13, 2024	EX-99.1	Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain Exhibit 99.1 Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain ● Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with u
May 22, 2024	EX-99.1	Sonnet BioTherapeutics Announces Review of Strategic Alternatives Exhibit 99.1 Sonnet BioTherapeutics Announces Review of Strategic Alternatives PRINCETON, NJ / ACCESSWIRE / May 22, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that its Board of Directors has initiated a process to explore and review a range of strategic alternatives fo
May 22, 2024	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
May 20, 2024	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
May 20, 2024	EX-99.1	Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target Exhibit 99.1 Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target ● The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levels ● Patients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of S
May 16, 2024	424B3	Up to 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279095 PROSPECTUS Up to 5,000,000 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by Chardan Capital Markets LLC (“Chardan” or the “Selling Securityholder”) of up to 5,000,000 shares of our common stock, $0.0001 par value per share (“Common Stock”), that have been or may be issued by us to Charda
May 15, 2024	S-1/A	As filed with the Securities and Exchange Commission on May 15, 2024 As filed with the Securities and Exchange Commission on May 15, 2024 Registration No.
May 15, 2024	CORRESP	May 15, 2024 May 15, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 14, 2024	EX-99.1	Presentation by Sonnet BioTherapeutics Holdings, Inc., dated May 14, 2024 Exhibit 99.1
May 14, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35570 SONNET BI
May 14, 2024	EX-99.1	Sonnet BioTherapeutics Holdings, Inc. Consolidated Balance Sheets (unaudited) Exhibit 99.1 Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update ● Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the FHAB-derived Interleukin 12 in healthy volunteers ● Announced early safety data from the company’s Phase 1b/2a clinical trial of SON-080 in patients with chemothera
May 14, 2024	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction (Commission (IRS Emplo
May 3, 2024	S-1	As filed with the Securities and Exchange Commission on May 3, 2024 As filed with the Securities and Exchange Commission on May 3, 2024 Registration No.
May 3, 2024	EX-10.1	ChEF Purchase Agreement, dated as of May 2, 2024, by and between Sonnet BioTherapeutics Holdings, Inc. and Chardan Capital Markets, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 3, 2024). Exhibit 10.1 Execution Version ChEF PURCHASE AGREEMENT This ChEF PURCHASE AGREEMENT is made and entered into as of May 2, 2024 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, the parties desire that, upon
May 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 SONNET BIOTHERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation) (
May 3, 2024	EX-10.2	Registration Rights Agreement, dated as of May 2, 2024, by and between Sonnet BioTherapeutics Holdings, Inc. and Chardan Capital Markets, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on May 3, 2024). Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 2, 2024 is by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”). RECITALS The Company and the Investor have entered into that certain ChEF P
May 3, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
March 11, 2024	EX-99.1	Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective Exhibit 99.1 Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective ● Safety in the Phase 1b part of Sonnet’s double-blind, randomized, controlled trial of SON-080 was reviewed by the study’s Data Safety Monitoring Board (DSMB) ● The adverse even
March 11, 2024	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction (Commission (IRS
March 6, 2024	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporation)
February 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35570 SONNET
February 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 14, 2024 SONNET BIOTHERA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 14, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporat
February 14, 2024	EX-99.1	Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update Exhibit 99.1 Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update ● Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offering ● Extensive preclinical data on SON-1210 published in Frontiers in Immunology ● Received approval and executed agreement to sell New Jersey state net operating losses (NOLs) for expected
February 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 SONNET BIOTHERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporati
January 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 SONNET BIOTHERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporati
January 3, 2024	CORRESP	January 3, 2024 January 3, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
January 2, 2024	SC 13G/A	US83548R3030 / SONNET BIOTHERAP / Markey John Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R303 (CUSIP Number) January 02, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
December 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 SONNET BIOTHERA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporat
December 22, 2023	EX-4.6	Form of Subordinated Note (included in Exhibit 4.6).* Exhibit 4.6 SONNET BIOTHERAPEUTICS HOLDINGS, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between SONNET BIOTHERAPEUTICS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapp
December 22, 2023	EX-FILING FEES	Filing Fee table* Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
December 22, 2023	S-3	As filed with the Securities and Exchange Commission on December 22, 2023 As filed with the Securities and Exchange Commission on December 22, 2023  Registration No.
December 22, 2023	EX-4.5	Form of Senior Note (included in Exhibit 4.5).* Exhibit 4.5 SONNET BIOTHERAPEUTICS HOLDINGS, INC., as Issuer and ● , as Trustee INDENTURE Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between SONNET BIOTHERAPEUTICS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicab
December 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 SONNET BIOTHERA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporat
December 14, 2023	EX-4.8	Description of Securities* Exhibit 4.8 DESCRIPTION OF SONNET BIOTHERAPEUTICS HOLDINGS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of September 30, 2023, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our voting common stock, $0.0001 par value per share and pr
December 14, 2023	EX-21.1	Subsidiaries of the Company (incorporated by reference to Exhibit 21.1 to the Company’s Annual Report on Form 10-K filed with the SEC on December 14, 2023). Exhibit 21.1 Subsidiaries of Sonnet BioTherapeutics Holdings, Inc. Name: Jurisdiction of Organization Sonnet BioTherapeutics, Inc. New Jersey Sonnet BioTherapeutics CH SA Switzerland SonnetBio Pty Ltd Australia
December 14, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35570 SONNET BIOTHE
December 14, 2023	EX-99.1	Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update Exhibit 99.1 Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs focused on oncology, announced today its financial results for the fiscal year ended September 30th, 202
December 14, 2023	EX-97.1	Clawback Policy* Exhibit 97.1 SONNET BIOTHERAPEUTICS, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on November 21, 2023) 1. Purpose Sonnet BioTherapeutics, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has adopted t
December 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2023 SONNET BIOTHERA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporat
November 17, 2023	SC 13G/A	SONN / Sonnet BioTherapeutics Holdings Inc / Markey John - 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R303 (CUSIP Number) November 17, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
November 6, 2023	SC 13G/A	SONN / Sonnet BioTherapeutics Holdings Inc / Markey John - AMENDED 13G Passive Investment SC 13G/A 1 sonna1110623.htm AMENDED 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R303 (CUSIP Number) November 06, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate
October 26, 2023	424B4	1,306,250 Shares of Common Stock 1,537,500 Pre-Funded Warrants to Purchase up to 1,537,500 Shares of Common Stock 5,687,500 Common Warrants to Purchase up to 5,687,500 Shares of Common Stock 85,312 Underwriter Warrants to Purchase up to 85,312 Shares Filed Pursuant to Rule 424(b)(4) Registration No. 333-274581 PROSPECTUS 1,306,250 Shares of Common Stock 1,537,500 Pre-Funded Warrants to Purchase up to 1,537,500 Shares of Common Stock 5,687,500 Common Warrants to Purchase up to 5,687,500 Shares of Common Stock 85,312 Underwriter Warrants to Purchase up to 85,312 Shares of Common Stock 1,537,500 Shares of Common Stock issuable upon exercise of th
October 23, 2023	CORRESP	October 23, 2023 October 23, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Mr. Dillon Hagius Re: Sonnet BioTherapeutics Holdings, Inc. Registration Statement on Form S-1 File No. 333-274581 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: October 24, 2023 Requested Time: 4:30 pm, Eastern Time Ladies and Gentlemen:
October 23, 2023	CORRESP	October 23, 2023 October 23, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
October 19, 2023	S-1/A	As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No.
October 4, 2023	S-1/A	As filed with the Securities and Exchange Commission on October 4, 2023 As filed with the Securities and Exchange Commission on October 4, 2023 Registration No.
October 4, 2023	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 SONNET BIOTHERAPEUTICS HOLDINGS, INC. UNDERWRITING AGREEMENT October [ · ], 2023 CHARDAN CAPITAL MARKETS, LLC 17 State Street, Suite 2100 New York, NY 10004 LADENBURG THALMANN & CO. INC. 640 5th Avenue, 4th Floor New York, NY 10019 As Representatives of the several Underwriters (as defined herein) Ladies and Gentlemen: Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the
October 4, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
September 28, 2023	CORRESP	September 28, 2023 September 28, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
September 28, 2023	S-1/A	As filed with the Securities and Exchange Commission on September 28, 2023 As filed with the Securities and Exchange Commission on September 28, 2023 Registration No.
September 28, 2023	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 SONNET BIOTHERAPEUTICS HOLDINGS, INC. UNDERWRITING AGREEMENT [ ], 2023 CHARDAN CAPITAL MARKETS, LLC 17 State Street, Suite 2100 New York, NY 10004 LADENBURG THALMANN & CO. INC. 640 5th Avenue, 4th Floor New York, NY 10019 As Representatives of the several Underwriters (as defined herein) Ladies and Gentlemen: Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”)
September 28, 2023	EX-4.16	Form of Common Warrant (filed as Exhibit 4.16 to the Company’s Registration Statement on Form S-1/A as filed on September 28, 2023, and incorporated herein by reference). Exhibit 4.16 FORM OF COMMON WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: [ ], 2023 (“Issuance Date”) Sonnet BioTherapeutics Holdings, Inc., a company organized under the law of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of
September 28, 2023	CORRESP	September 28, 2023 September 28, 2023 VIA EDGAR CORRESPONDENCE U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Dillon Hagius Re: Sonnet BioTherapeutics Holdings, Inc. Registration Statement on Form S-1 Filed September 28, 2023 File No. 333-274581 WITHDRAWAL OF REQUEST FOR ACCELERATION OF EFFECTIVENESS Dear Mr. Hagius: Reference is made
September 28, 2023	EX-4.14	Form of Pre-Funded Warrant (filed as Exhibit 4.14 to the Company’s Registration Statement on Form S-1/A as filed on September 28, 2023, and incorporated herein by reference). Exhibit 4.14 FORM OF PRE-FUNDED WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: [ ] (“Issuance Date”) Sonnet BioTherapeutics Holdings, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and suff
September 28, 2023	CORRESP	September 28, 2023 September 28, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
September 28, 2023	EX-4.15	Form of Underwriter Warrant (filed as Exhibit 4.15 to the Company’s Registration Statement on Form S-1/A as filed on September 28, 2023, and incorporated herein by reference). Exhibit 4.15 FORM OF UNDERWRITER WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: [●], 2023 Issue Date: [●], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [Chardan Capital Markets, LLC (“Chardan”)] [Ladenburg Thalmann & Co., Inc. (“Ladenburg”)], or its assigns (the “Holder”) is entitled, upon the terms and subject to
September 28, 2023	CORRESP	September 28, 2023 September 28, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Mr. Dillon Hagius Re: Sonnet BioTherapeutics Holdings, Inc. Registration Statement on Form S-1 File No. 333-274581 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: September 28, 2023 Requested Time: 4:30 pm, Eastern Time Ladies and Gentlem
September 19, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorpora
September 19, 2023	EX-99.1	Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance Exhibit 99.1 Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance PRINCETON, NJ / ACCESSWIRE / September 19, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market indicating that Sonnet has rega
September 19, 2023	S-1	As filed with the Securities and Exchange Commission on September 19, 2023 As filed with the Securities and Exchange Commission on September 19, 2023 Registration No.
September 19, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
September 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Sonnet BioTherape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Sonnet BioTherapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporatio
September 1, 2023	EX-3.1	Certificate of Amendment of Certificate of Incorporation, as amended, of Sonnet BioTherapeutics Holdings, Inc., dated August 31, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on September 1, 2023). Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF SONNET BIOTHERAPEUTICS HOLDINGS, INC. Sonnet BioTherapeutics Holdings, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: FIRST: That a resolution was duly adopted on August 31, 2023, by the Board of Dir
August 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Sonnet BioTherape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Sonnet BioTherapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporatio
August 31, 2023	EX-99.1	Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split Exhibit 99.1 Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split PRINCETON, NJ / ACCESSWIRE / August 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-22 reverse stock split of its outstanding common stock. This will be effective
August 22, 2023	EX-99.1	I wanted to connect with our shareholders to provide a business update and discuss future opportunities for our assets. Since our last shareholder meeting in September 2022, Sonnet has focused on business development, which we believe sets the stage Exhibit 99.1 Dear Sonnet Shareholders, August 22, 2023 I wanted to connect with our shareholders to provide a business update and discuss future opportunities for our assets. Since our last shareholder meeting in September 2022, Sonnet has focused on business development, which we believe sets the stage for two potential partnership opportunities that have been previously disclosed with Roche and
August 22, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
August 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2023 SONNET BIOTHERAPE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporatio
August 21, 2023	EX-FILING FEES	Filing Fee Table* Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
August 21, 2023	S-8	As filed with the Securities and Exchange Commission on August 21, 2023 As filed with the Securities and Exchange Commission on August 21, 2023 Registration No.
August 14, 2023	EX-99.1	Sonnet BioTherapeutics Holdings, Inc. Consolidated Balance Sheets Exhibit 99.1 Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update ● Combination study of SON-1010 with Roche’s atezolizumab (Tecentriq®) has been initiated in Australia ● First SON-1010 Phase 1 study has been completed and comparison of the human pharmacokinetic data supports targeting of tumor tissue ● Early safety data from the SON-080 trial in CIPN is expe
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35570 SONNET BIO
August 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 SONNET BIOTHERAPE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporatio
August 9, 2023	424B4	5,150,000 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-273516 5,150,000 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” of up to 5,150,000 shares of our common stock, par value $0.0001 per share (“Common Stock”)
August 7, 2023	SC 13G/A	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Markey John - 13G/A FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) August 07, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
August 7, 2023	CORRESP	August 7, 2023 August 7, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
August 7, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
July 28, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
July 28, 2023	S-1	As filed with the Securities and Exchange Commission on July 28, 2023 As filed with the Securities and Exchange Commission on July 28, 2023 Registration No.
July 28, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Sonnet BioTherapeutics Holdings, Inc.
July 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2023 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction of Incorporation) (Co
July 17, 2023	SC 13G/A	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Markey John - 13G FILING AMENDMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) July 17, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
July 7, 2023	SC 13G/A	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Markey John - 13G FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) July 07, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
June 30, 2023	SC 13G	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Markey John - 13G FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) June 30, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
June 30, 2023	EX-10.1	Form of Securities Purchase Agreement, dated June 28, 2023, by and between the Company and the Purchaser (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on June 30, 2023). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 28, 2023, between Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms a
June 30, 2023	EX-4.1	Form of Pre-Funded Warrant dated June 30, 2023 (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K, filed with the SEC on June 30, 2023). Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. Warrant Shares: [] Issue Date: [], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t
June 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 28, 2023 SONNET BIOTHERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 28, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction of Incorporation) (Co
June 30, 2023	EX-4.3	Form of Placement Agent Warrant dated June 30, 2023 (incorporated by reference to Exhibit 4.3 to Current Report on Form 8-K, filed with the SEC on June 30, 2023). Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 30, 2023	EX-4.2	Form of Warrant dated June 30, 2023 (incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K, filed with the SEC on June 30, 2023). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 30, 2023	EX-99.1	Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement Exhibit 99.1 Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement PRINCETON, NJ / ACCESSWIRE / June 28, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, today announced that it has entered into a definitive agreement with a single i
June 29, 2023	424B5	3,660,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,340,000 Shares of Common Stock 1,340,000 Shares of Common Stock Underlying the Pre-Funded Warrants PROSPECTUS SUPPLEMENT (To Prospectus dated December 29, 2020) Filed Pursuant to Rule 424(b)(5) Registration No.
June 22, 2023	SC 13G/A	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Ruck Matthew J Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) June 22, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
June 14, 2023	SC 13G/A	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Ruck Matthew J Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) June 14, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
June 14, 2023	SC 13G/A	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Ruck Matthew J Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) June 14, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
June 12, 2023	SC 13G	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Markey John - 13G FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) June 12, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
May 26, 2023	SC 13G/A	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Markey John - MARKEY JOHN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) May 25, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
May 17, 2023	SC 13G/A	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Markey John - MARKEY JOHN Passive Investment SC 13G/A 1 sonna151723.htm MARKEY JOHN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) May 17, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box t
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35570 SONNET BIOTHERAPEUTICS H
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 10, 2023 SONNET BIOTHERAPEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 10, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction of Incorporation) (Com
May 10, 2023	EX-99.1	Sonnet BioTherapeutics Holdings, Inc. Consolidated Balance Sheets Exhibit 99.1 Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update ● Additional data presented from two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors. Cytokine data reveal extended PK profile for SON-1010: - Induces prolonged and controlled IFNγ response - No evidence of cytokine release syndro
May 2, 2023	SC 13G	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Markey John - MARKEY JOHN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) COM NEW (Title of Class of Securities) 83548R204 (CUSIP Number) April 28, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
April 18, 2023	EX-99.1	Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting Exhibit 99.1 Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting ● The SB101 and SB102 Phase 1 studies have together dosed 46 subjects to date as SB101 dose escalation continues ● Cytokine data reveals extended PK profile for SON-1010 ○ Induces prolonged and controlled IFNγ response ○ No evidence of cytokine
April 18, 2023	EX-99.2	Presentation by Sonnet BioTherapeutics Holdings, Inc., dated April 18, 2023. Exhibit 99.2
April 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2023 SONNET BIOTHERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction (Commission (IRS Emp
March 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 SONNET BIOTHERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction of Incorporation) (C
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 10, 2023 SONNET BIOTHERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 10, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction of Incorporation) (C
February 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35570 SONNET BIOTHERAPEUTIC
February 13, 2023	EX-99.1	Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering Exhibit 99.1 Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering PRINCETON, NJ / ACCESSWIRE / February 8, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a clinical-stage company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 13,888,888 shares of common stock
February 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 SONNET BIOTHERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35570 20-2932652 (State or other jurisdiction of incorporati
February 13, 2023	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 13, 2023 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35570 20-2932652 (State or Other Jurisdiction of Incorporation)
February 13, 2023	EX-4.3	Form of Underwriter Warrant dated February 10, 2023 (incorporated by reference to Exhibit 4.3 to our Current Report on Form 8-K filed with the SEC on February 13, 2023). Exhibit 4.3 FORM OF UNDERWRITER WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: February 10, 2023 Issue Date: February 10, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an
February 13, 2023	EX-99.1	Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update Exhibit 99.1 Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update ● Data announced from two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors ● Entered into collaboration with Janssen Biotech for the evaluation of three Sonnet pipeline compounds ● Successfully completed two IND-enabling toxicology studies with SON-
February 13, 2023	EX-4.4	Form of Common Warrant dated February 10, 2023 (incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed with the SEC on February 13, 2023). Exhibit 4.4 COMMON WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: February 10, 2023 (“Issuance Date”) Sonnet BioTherapeutics Holdings, Inc., a company organized under the law of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of
February 13, 2023	EX-4.2	Form of Pre-Funded Warrant dated February 10, 2023 (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on February 13, 2023). Exhibit 4.2 PRE-FUNDED WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: February 10, 2023 (“Issuance Date”) Sonnet BioTherapeutics Holdings, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and
February 13, 2023	EX-1.1	Underwriting Agreement, dated February 8, 2023, between the Company and Chardan Capital Markets, LLC (incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed with the SEC on February 13, 2023). Exhibit 1.1 13,888,888 Shares of Common Stock (or Pre-Funded Warrants to Purchase Shares of Common Stock in Lieu Thereof) Warrants to Purchase 27,777,776 Shares of Common Stock SONNET BIOTHERAPEUTICS HOLDINGS, INC. UNDERWRITING AGREEMENT February 8, 2023 CHARDAN CAPITAL MARKETS, LLC as Representative of the several Underwriters named on Schedule I hereto 17 State Street, Suite 2100 New York, NY 10
February 10, 2023	SC 13G/A	US83548R2040 / Sonnet BioTherapeutics Holdings, Inc. / Hudson Bay Capital Management LP - SONN 13GA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sonnet BioTherapeutics Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 83548R204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 9, 2023	424B4	11,664,888 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,224,000 Shares of Common Stock Common Warrants to Purchase up to 27,777,776 Shares of Common Stock Shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-269307 11,664,888 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,224,000 Shares of Common Stock Common Warrants to Purchase up to 27,777,776 Shares of Common Stock Shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants We are offering up to 11,664,888 shares of our common stock and common warran
February 7, 2023	FWP	SONNET BIOTHERAPEUTICS HOLDINGS, INC. Free Writing Prospectus Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated February 7, 2023 Relating to Preliminary Prospectus dated February 6, 2023 Registration No.
February 6, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Sonnet BioTherapeutics Holdings, Inc.

SONN / Sonnet BioTherapeutics Holdings, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)